Controversy surrounding the increased expression of TGFβ1 in asthma by Bossé, Ynuk & Rola-Pleszczynski, Marek
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Respiratory Research
Open Access Review
Controversy surrounding the increased expression of TGFβ1 in 
asthma
Ynuk Bossé and Marek Rola-Pleszczynski*
Address: Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada
Email: Ynuk Bossé - ybosse@mrl.ubc.ca; Marek Rola-Pleszczynski* - Marek.Rola-Pleszczynski@USherbrooke.ca
* Corresponding author    
Abstract
Asthma is a waxing and waning disease that leads to structural changes in the airways, such as
subepithelial fibrosis, increased mass of airway smooth muscle and epithelial metaplasia. Such a
remodeling of the airways futher amplifies asthma symptoms, but its etiology is unknown.
Transforming growth factor β1 is a pleiotropic cytokine involved in many fibrotic, oncologic and
immunologic diseases and is believed to play an essential role in airway remodeling that occurs in
asthmatic patients. Since it is secreted in an inactive form, the overall activity of this cytokine is not
exclusively determined by its level of expression, but also by extensive and complex post-
translational mechanisms, which are all importanin modulating the magnitude of the TGFβ1
response. Even if TGFβ1 upregulation in asthma is considered as a dogma by certain investigators
in the field, the overall picture of the published litterature is not that clear and the cellular origin
of this cytokine in the airways of asthmatics is still a contemporaneous debate. On the other hand,
it is becoming clear that TGFβ1 signaling is increased in the lungs of asthmatics, which testifies the
increased activity of this cytokine in asthma pathogenesis. The current work is an impartial and
exhaustive compilation of the reported papers regarding the expression of TGFβ1 in human
asthmatics. For the sake of comparison, several studies performed in animal models of the disease
are also included. Inconsistencies observed in human studies are discussed and conclusions as well
as trends from the current state of the litterature on the matter are proposed. Finally, the different
points of regulation that can affect the amplitude of the TGFβ1 response are briefly revised and the
possibility that TGFβ1 is disregulated at another level in asthma, rather than simply in its
expression, is highlighted.
Transforming growth factor β1
Transforming growth factor (TGF)β1 is an intercellular
signaling molecule that demonstrates a plethora of bio-
logic effects in both in vitro and in vivo contexts. It was first
isolated and characterized in platelets in 1983 [1] and is
now the prototype member of a superfamily of cytokines,
which actually counts 33 members in man [2]. For taxo-
nomic purpose, members of the TGFβ superfamily are fur-
ther divided into subgroups, and together with its two
closest homologues TGFβ2 and TGFβ3, TGFβ1 forms the
TGFβ subfamily.
TGFβ1 is synthesized as a prepropeptide of 390 aa and is
encoded by a 7-exon gene (TGFB1) localized on chromo-
some 19q13.2. Several genetic studies have associated
some of the common single nucleotide polymorphisms
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(SNP) found in the TGFB1  gene or its promoter with
asthma phenotypes, supporting its potential role in the
pathogenesis of this disease [3-8]. The gene is ubiqui-
tously expressed, but its level of expression is transcrip-
tionally and post-transcriptionally regulated. The
maturation, expression and activation of the protein are
also subject to extensive and complex post-translational
regulation. Following its cleavage from the 29 aa signal
peptide, the propeptide homodimerizes and both pro-
tomeres are cleaved by furin, a ubiquitous subtilisin-like
proprotein convertase localized in the trans-Golgi net-
work, at a canonic RX(K/R)R furin cleavage site found at
position 275–278 on the TGFβ1 propeptide [9]. This pro-
teolytic maturation generates the homodimeric mature
protein, in which each of the 112-aa long protomeres
remains associated due to hydrophobic interactions and a
disulfide bridge [10]. This active form of TGFβ1 demon-
strates a short half-life (normally less than 3 min) in cell-
free systems [11]. To overcome its lability in in vivo condi-
tions and to avoid premature binding with its cognate
cell-surface receptor, TGFβ1 remains non-covalently asso-
ciated with its propeptide latency-associated peptide
(LAP). This post-translational modification renders
TGFβ1 inactive during and after the secretory process.
Latent TGFβ1 can also be secreted as a larger 180–210-KD
multi-protein complex, which includes, in addition to the
75-KD LAP and the 25-KD mature TGFβ1 protein, the gly-
cosylated 125–190-KD latency TGFβ binding protein
(LTBP) [12].
Extracellular activation of latent TGFβ1 occurs through
different mechanisms including: 1- proteolytic dissocia-
tion from LAP by the urokinase plasminogen activator
(uPA)/plasmin system [13,14], or by other proteases such
as metalloproteinase (MMP)-2 [9], MMP-9 [15,16] and
the lysosomal serine protease cathepsin D [13]; 2- confor-
mational alteration in its structure by thrombospondin
[17] or integrins such as the αvβ6 integrin [18,19]; 3- oxi-
dation and nitrosylation [20,21]; 4- removal of carbohy-
drate structure on LAP by glycosidases such as sialidase
[22]; 5- integrin αvβ8-mediated latent TGFβ1 recruitment
to the cell membrane for membrane type 1 (MT1)-MMP-
dependent proteolytic activation [23]; and 6- extremes of
pH or high concentrations of urea [24]. Mannose 6-phos-
phate/insulin-like growth factor II (IGF-II) receptor
[25,26] as well as integrins α8β1 [27] and αvβ1 [28] also
bind latent forms of TGFβ1 and are thus believed to target
the latent complex on the surface of cells for subsequent
proteolytic activation and ensuing binding to its signaling
receptor. TGFβ1 is also a heparin binding growth factor
(HBGF) [29,30]. Consequently, its binding availability for
cell surface receptors is regulated extracellularly by
heparan sulfate proteoglycans (HSPG). Whereas certain
proteoglycans, such as betaglycan and endoglin [31],
facilitate TGFβ1 binding to its receptors; others, such as
biglycan, fibromodulin and decorin, sequester TGFβ1 in
the ECM [32,33]. In addition, certain enzymes that cannot
activate latent TGFβ1 directly, such as thrombin, neu-
trophil elastase or mast cell chymase may also be involved
in the process of TGFβ1 activation owing to their ability to
release TGFβ1 from pericellular stores [34,35].
TGFβ1 receptors and signaling
Six receptors have been identified for TGFβ1 [36], but the
most studied are the 65-KD type I receptor (Tβ RI or ALK-
5), the 85-KD type II receptor (Tβ RII), the 280-KD type III
receptor (Tβ RIII or betaglycan, a heparan sulfate/chon-
droitin sulfate proteoglycan), and more recently the 504-
KD Tβ R5, which is also known as the low-density lipo-
protein receptor-related protein 1 (LRP1). The canonic
mechanisms by which TGFβ1 binds and activates its cog-
nate type I and type II cell surface receptors as well as the
intracellular signaling pathways that transduce TGFβ1
messages from the cell membrane to the nucleus have
been reviewed extensively [10]. Briefly, TGFβ1 initially
binds to the single transmembrane, constitutively active,
serine/threonine kinase Tβ RII homodimer. The formed
complex subsequently recruits the single transmembrane,
activable, serine/threonine kinase Tβ RI homodimer,
which is concomitantly activated by Tβ RII-mediated
phosphorylation of several threonine and serine residues
in its intracellular GS juxtamembrane domain. This phos-
phorylated GS domain then serves as a docking site for
activin-receptor activated Smads (AR-Smads; namely
Smad2 and Smad3), which are, in turn, phosphorylated
by Tβ R1. The phospho-AR-Smads (pSmad2 and pSmad3)
then homo or hetero-oligomerize with each other and
with at least one co-mediator Smad (Co-Smad; most often
called Smad4) and the complex ultimately translocates to
the nucleus where it binds Smad binding element (SBE)-
containing promoters or interacts with other transcrip-
tional partners to regulate gene expression. Apart from the
Smad pathway, it is now clear that other intracellular sig-
naling pathways such as mitogen-activated protein kinase
(MAPK), the phosphoinositide 3-kinase (PI3K), the PP2A
phosphatase-mediated p70S6K inactivation and the Rho-
family of small guanosine triphosphatase (GTPase) path-
ways are activated by TGFβ1 and transduce some of its
biological activities (reviewed in [37] and [38]). In addi-
tion, Smads were shown to cross talk with other impor-
tant signaling pathways such as Janus kinase-Signal
transduction and activator of transcription (JAK-STAT)
[39] and WNT [40].
The overall activity of TGFβ1 can thus be regulated at dif-
ferent levels. Any default in proteins involved in the proc-
esses that regulate TGFβ1 expression, maturation,
secretion, extracellular trafficking and localization, activa-
tion/inhibition and binding on its multiple receptors, as
well as any default in receptor expression/function/distri-Respiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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bution or in the different signaling intermediate mole-
cules that transduce its biological effects intracellularly are
susceptible to influence TGFβ1 response.
TGFβ2 and TGFβ3 also bind and signal through the same
cell-surface Tβ RI and Tβ RII. Consequently, these
cytokines share several biological activities in vitro and it
is thus believed that they can substitute for each other's
function in vivo. However, knock-outs of each of these
individual genes have demonstrated non-overlapping
functions of these proteins in vivo [41-43]. These results
may stem from their different promoters, which suggests
different expression patterns and regulation [44]. In addi-
tion, TGFβ2, but neither TGFβ1 nor TGFβ3, required Tβ
RIII (betaglycan) to manifest its effector functions.
Whether this is related to a three-amino acid divergence
that affects the binding affinity to Tβ RII between the
sequence of TGFβ2 and the two other isoforms [45] or the
lack of RGD sequence in TGFβ2 (which is necessary for
cell-surface integrin interaction and concomitant three
dimensional-positioning that allows the ligand to access
its cognate receptor on cellular plasmalemma) is still a
contemporaneous debate, but Tβ RIII is definitely a pre-
requisite for TGFβ2 activity [46]. This peculiarity confers
cell-specific activity to TGFβ isoforms, such that only cells
expressing the Tβ RIII can response to TGFβ2, and may
thus contribute to the non-redundant effects of these
cytokines in vivo.
Disregulation of TGFβ1 activity has previously been
shown to be involved in a diverse spectrum of pathologic
conditions, such as cancer, autoimmunity and fibrotic dis-
eases. The potential role for TGFβ1 in asthma pathogene-
sis has also been reviewed recently [44,47,48]. However,
this last assertion is based on the conjecture that TGFβ is
overexpressed in asthma. Unfortunately, the studies inves-
tigating the expression of TGFβ1 in asthma have yielded
inconsistent results. The first purpose of the current work
is to review the published data concerning the expression
of TGFβ1 in asthma and to discuss the cellular sources to
this cytokine in this particular disease. Secondly, recent
evidence that TGFβ1 signaling is activated in the airways
of asthmatics is presented and a hypothesis is proposed
that TGFβ1 overactivation in asthma may not rely exclu-
sively on its increased expression, but may be related to
different alterations in other points of regulation that
modulate TGFβ1 activity.
Expression of TGFβ1 in asthma
Expression of TGFβ1 is altered in asthma and the current
weight of evidence suggests that TGFβ1 is upregulated in
human and animal asthmatic airways (summarized in
Table 1 [see additional file 1], Table 2 [see additional file
2], and Figure 1). However, 6 studies performed with
human tissues have shown no regulation of TGFβ1
expression in asthma. In contrast to their previous articles,
in which they reported an increased expression of TGFβ1
in bronchoalveolar lavage fluid (BALF) before and after
allergic challenge [49], Redington and coworkers [32]
have demonstrated indistinguishable pattern of TGFβ1
immunohistochemical staining between asthmatic and
control subjects. Aubert and coworkers [50] had previ-
ously reported similar findings, but their results were con-
tested since their control subjects were heavy smokers. The
relative intensity of TGFβ1 immunostaining in the bron-
chial mucosa was also similar between asthmatics and
Compilation of studies investigating the expression of TGFβ expression in human asthma Figure 1
Compilation of studies investigating the expression of TGFβ expression in human asthma.
Increased Not regulated
Ohno et al., 1996
Vignola et al., 1996
Magnan et al., 1997
Vignola et al., 1997
Redington et al., 1997
Minshall et al., 1997
Tillie-Leblond et al., 1999
Wenzel et al., 1999
Prieto et al., 2000
Chu et al., 2000
Hastie et al., 2002
Nomura et al., 2002
Chakir et al., 2003
Berger et al., 2003
Joseph et al., 2003
Kokturk et al., 2003
Batra et al., 2004
Karagiannidis et al., 2006
Matsunaga et al., 2006
Aubert et al., 1994
Redington et al., 1998
Hoshino et al., 1998
Chu et al., 1998
Chu et al., 2004
Balzar et al., 2005
Torrego et al., 2007Respiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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healthy subjects in Hoshino and coworkers' study [51].
More recently, two papers published by the same group
confirmed these results by documenting a lack of signifi-
cant augmentation of TGFβ1 immunoreactivity in asth-
matic epithelium [52], as well as no difference in the
number of cells staining positive for TGFβ1 in the submu-
cosa of normal subjects and asthmatic patients suffering
from different severity of the disease [53].
Reasons for these discrepancies are currently unknown.
However, all conflicting results came from studies meas-
uring TGFβ1 expression by immunohistochemical
approaches, using tissue specimens obtained by bronchial
biopsies or lung resections. Immunohistochemistry
requires extensive tissue handling. All the steps before
microscopic reading, including immediate precaution to
preserve tissue integrity, reagents used for fixation or to
embed the tissue, strength and specificity of the detection
and the staining antibodies, and bleaching of the fluoro-
chrome or attenuated chemiluminescence signal occur-
ring during the procedures could all lead to erroneous
results and false interpretations. It is thus reasonable to
surmise that the conflicting results concerning the
increased expression of TGFβ1 in the airways of asthmat-
ics may be the result of technical artefacts. However, alter-
native hypotheses may explain this conundrum.
Temporal concerns
It is worth mentioning that collection of lung specimens
offers conspicuous advantages for studying mRNA or pro-
tein expression at the tissue level. For example, staining of
cross-sectional sections of these lung specimens by immu-
nohistochemical approach or by in situ hybridization
brings ample information regarding the tissue or the cel-
lular sources of TGFβ1. Combined with laser microdissec-
tion, tissue specific expression of a particular gene can
even be confirmed using more conventional techniques
such as RT-PCR [54]. Unfortunately, limits of these tech-
niques are also prominent. As such, results obtained from
these experiments must be interpreted with caution. Pro-
tein or mRNA detected in lung specimens reflect their
expression levels at a particular time point. Asthma is a
waxing and waning disease, where a period of exacerba-
tion is usually followed by a period of remission and
where the severity of symptoms is temporally associated
with the degree of airway inflammation. Therefore, upreg-
ulation of asthma mediators, such as TGFβ1, is also likely
to be inducible and transient in nature. Accordingly,
TGFβ1 was shown to be increased at 24 h, but not at 10
min, following segmental allergic challenge (SAC) and its
concentration returned to baseline level after 1 week
[49,55]. Whether TGFβ1 expression starts to increase ear-
lier is unknown, but in animal models of acute or chronic
antigen challenge, TGFβ1 expression in BALF is still unaf-
fected 6 h following the previous allergen exposure [56].
In contrast to Batra and coworkers [55], Redington and
coworkers [49] also reported a statistically significant
increase in TGFβ1 level in asthmatics at baseline com-
pared to healthy controls (8 pg/ml vs 5.5 pg/ml), but
whether this difference is physiologically relevant remains
questionable. Tillie-Leblond and coworkers [57] have also
reported no difference in the levels of latent and active
forms of TGFβ1 in BALF at baseline between mild asth-
matics and healthy volunteers. In the same study, both the
latent and active form of TGFβ1 were significantly
increased in patients suffering from status asthmaticus
compared to healthy controls or to patients presenting
similar severity of the disease, but distant from an acute
exacerbation period. Nomura and coworkers [58] have
substantiated these results by examining longitudinal
changes that occur in the lung function (forced expiratory
volume in 1 sec, % of predicted (%FEV1)) and the per-
centage of TGFβ1 positive cells in induced sputum sam-
ples of five asthmatic subjects. They demonstrated that
during asthma exacerbation, %FEV1 decreased from 86.5
to 51.0% and that TGFβ1 positive cells rose from 1.9 to
55.4% during the same time period. These results con-
firmed the inducible and transient upregulation of TGFβ1
that has been demonstrated by others in BALF following
SAC [49,55]. Based on results obtained with animal mod-
els of chronic allergen challenge-induced airway remodel-
ling, it was also suggested that several allergen
provocations may be required before the upregulation of
TGFβ1 could be appreciated [59].
These aformentioned findings suggest that the samples
would need to be collected following bronchoprovoca-
tion to observe the transient increase in TGFβ1 expression
by immunohistochemistry. In all studies documenting an
absence of regulation of TGFβ1 expression in asthma,
lung specimens had been taken at baseline, i.e. in a remis-
sion period where no sign of exacerbation was present or
without prior experimentally-induced bronchoprovoca-
tion. In Hoshino and coworkers' study [51] for example,
asthmatics presented daily symptoms, but based on their
attack score, the number and severity of symptoms were
very low, suggesting that subjects were not in an exacerba-
tion period when biopsies were taken. In the immunohis-
tochemical study carried out by Redington and coworkers
[32], asthmatic subjects were presented as mildly sympto-
matic. However, they were clinically stable despite being
restricted from use of oral or inhaled glucocorticoids for 4
weeks, indicating once again that no acute exacerbation
was present at the time bronchial biopsies were taken.
Hence, failure to demonstrate a significant upregulation
may simply reflect the punctual expression of TGFβ1
measured in the two extreme poles of a transient
response. Taken together, these results imply that TGFβ1
is not necessarily overexpressed in asthmatics at baseline,
but is inducible upon allergen challenge. Determining theRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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sequence and the kinetics of TGFβ1 expression may be
important to increase our understanding of the role of this
cytokine in asthma.
Spatial concerns
In striking contrast with the results obtained by Redington
and coworkers [49] and Batra and coworkers [55] in BALF,
no regulation of TGFβ1 immunostaining was observed in
the bronchial mucosa of asthmatics 24 h following aller-
gen challenge [60]. This later study equally showed that
the percentages of peribronchial eosinophils and neu-
trophils staining positive for TGFβ1 were identical follow-
ing either saline or allergen challenges. Since the number
of both of these cells was shown to be increased in this
particular tissue after allergen challenge in their study, one
might expected that if the percentage of cells expressing
the cytokine remains similar, the absolute amount of
TGFβ1 will be upregulated. And this will likely be
reflected in the BALF, as observed by the previous groups
[49,55]. It is unfortunate that the authors did not com-
ment on this last possibility. Taken together, these results
suggest that the failure to detect an increased expression of
TGFβ1 in certain immunohistochemical studies may sim-
ply be related to the airway tissue studied.
Expression of TGFβ was also shown to be heterogenous
within the same sample [61] and its increased expression
in asthma may occur exclusively in very localized com-
partments. For instance, periglandular tissues or sites of
epithelial desquamation were shown to stain strongly for
this cytokine [61,62]. On the other hand, Magnan and
coworkers [63] have demonstrated homogenous intensity
of TGFβ immunostaining in ciliated and mucous cells as
well as in areas of epithelial impairment, such as sites of
deciliated cells or desquamated regions. However, apart
from a homogenous staining in the epithelium within
each sample, Magnan and coworkers [63] suggested an
altered compartmentalization of TGFβ expression in asth-
matic airways. Whereas TGFβ immunoreactivity was
strong in the epithelium of control subjects, negative or
faintly positive staining was observed in this particular
compartment of asthmatics. In contrast, asthmatics
expressed higher amounts of TGFβ in the submucosa
compared to healthy individuals. This epithelial to sub-
mucosal redistribution of TGFβ was in accordance with an
increased number of inflammatory cells staining positive
for TGFβ in the submucosa of human asthmatics [61,64-
68].
Whatever the physiologic or pathophysiologic reason for
this altered compartmentalization, the same trend of
TGFβ1 relocalization was observed in murine models of
allergic airway inflammation. In this regard, McMillan
and coworkers [69] have demonstrated that TGFβ1
expression was confined to the bronchiolar and alveolar
epitheliums in control animals and was relocalized to the
submucosal compartment in association with inflamma-
tory infiltrates after repeated allergen challenges of sensi-
tized animals. In this particular model, even smooth
muscle became positive for TGFβ1 immunostaining dur-
ing the chronic phase of allergen challenge. Interestingly,
this altered compartmentalization also occurred in other
types of airway inflammation, such as the one induced by
prolonged (4 wk) lipopolysaccharide (LPS) exposure
[70]. Initially, TGFβ1 expression was confined to the air-
way epithelium, but subsequent to LPS exposure, TGFβ1
immunostaining was mainly localised in the subepithe-
lium area [70]. Hence, in addition to looking at the right
time, investigators attempting to document an increased
expression of TGFβ1 in asthma need to look at the right
place.
With the use of techniques permitting to appreciate the
overall expression of TGFβ1, such as in studies using
BALF, serum or plasma, or with the use of animal models,
which allow sufficient biologic materials to be homoge-
nized, it is becoming clear that TGFβ1 is upregulated in
asthma following allergic challenge. But once again, con-
troversies are reported and are related to different peculi-
arities of the studied populations. For example, Joseph
and coworkers [71] have reported an increase in TGFβ1
expression in the plasma of nonatopic, but not of atopic
asthmatic patients. However, using only atopic patients,
which were included based on skin prick test positivity
and corroborating medical history of allergen-induced
asthma, Karagiannidis and coworkers [72] reported a sig-
nificant increase of TGFβ1 in the serum of asthmatics,
attaining levels almost 7-fold higher than those measured
in healthy controls. No clear explanation is currently pro-
posed to explain these contrasting results and the ques-
tion of whether TGFβ1 expression is influenced by the
atopic status will need further exploration.
Increased expression of TGFβ1 measured in the BALF
must also be interpreted with caution. Epithelium desqua-
mation is a characteristic feature of remodeled asthmatic
airways. Epithelium denudation may give access to a cer-
tain amount of TGFβ1, which is otherwise masked by an
intact epithelium in non-asthmatic individuals. Thus, the
increased expression of TGFβ1 observed in BALF of asth-
matics following challenge may simply be related to an
easier accessibility to TGFβ1 stores cause by epithelium
desquamation. In support of this contention, increased
concentration of TGFβ1 has been noted in BALF following
a sham bronchoprovocation procedure, which is likely to
be the result of epithelial damage [49]. Moreover, a posi-
tive correlation (r = 0.89) has been reported in the same
study between concentration of TGFβ1 and the number of
epithelial cells collected in BALF of the saline-challenged
site. These results suggest that epithelium denudationRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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renders a bulk of TGFβ1 normally sequestered in the sub-
epithelial layer, such as the one associated with the basal
lamina [32,50], collectable by bronchoalveolar lavage. Of
major concern, degranulation products of eosinophils
such as major basic protein (MBP) and eosinophil cati-
onic protein (ECP) [73,74], as well as mast cell proteases,
such as tryptase and chymase [75], are damaging for the
airway epithelium. Increased expression of TGFβ1
observed at 24 h, but not at 10 min, following SAC may
consequently be caused by eosinophil- or mast cell-medi-
ated epithelium desquamation, rather then a true de novo
protein synthesis of TGFβ1. Together, these observations
raise doubts on the techniques currently used to measure
the expression of different mediators in the airways and,
for instance, the increased expression of TGFβ1 in asthma.
Cellular sources of TGFβ1 in asthma
Studies investigating the cellular source of TGFβ1 in
asthma have also yielded inconsistent results. It is known
that TGFβ1 is widely expressed throughout the body and
that every resident structural and immune cell in the lung,
as well as every inflammatory cell mobilised to the air-
ways during asthma exacerbation, is able to express and
secrete TGFβ1. In the lungs of non-asthmatic humans or
animals, airway epithelium seems to be the major site of
TGFβ1 expression [16,63,76-80]. However, other stromal
cells in the airways such as fibroblasts [61,81-83],
endothelial cells [84], vascular smooth muscle (VSM)
cells [78] and airway smooth muscle (ASM) cells
[50,62,77,78,85-90] are also potential source of this
cytokine since they were all shown to express and produce
detectable amount of TGFβ1. Due to its affinity to certain
components of the ECM, latent forms of TGFβ1 in the
lung have a tendency to accumulate in particular compart-
ments of the airway wall. In fact, many immunohisto-
chemical studies have localized TGFβ1 mainly in
extracellular compartments in association with connec-
tive tissues of the airway wall [32,50,62]. However, the
cellular sources of ECM-sequestered TGFβ1 are difficult to
determine. In contrast to these results, Magnan and cow-
orkers [63] were unable to identify TGFβ expression in
extracellular space, but rather identified inflammatory
cells infiltrating the submucosa and the epithelium as the
major source of this cytokine. One could speculate that
this controversy may be related to the use of a pan-TGFβ
antibody (Ab) in this latter study, but the detection of all
three forms of TGFβ instead of TGFβ1 only would be an
additional reason to find TGFβ in extracellular spaces.
Neutrophils
In asthma, the cellular origin of TGFβ1 is less clear and
numerous inflammatory cells as well as structural cells
were shown to contribute. Blood- or airway-derived neu-
trophils in normal and asthmatic individuals were shown
to express TGFβ [60,66,91]. Since, airway neutrophilia is
particularly prominent in nonatopic asthma [92] and in
more severe forms of the disease (reviewed in [93]), neu-
trophils could contribute significantly to the increased
expression of TGFβ in these types of asthma. In this
regard, Chu and coworkers [66] have demonstrated that
around 55% of TGFβ-positive cells in the submucosal
compartment of asthmatics and normal controls were
neutrophils [66]. However, only a fraction of neutrophils
expressed TGFβ (29 and 20% in asthmatic and normal
submucosa, respectively). In animals, increased TGFβ1
expression in the subepithelial area following prolonged
(4 weeks) exposure to LPS was also neutrophil-depend-
ent, as neutropenic animals did not develop this altered
expression of TGFβ1 [70]. Interestingly, upregulation of
TGFβ1 expression in the airway epithelium observed after
a recovery period of 4 weeks following exposure to LPS
was also dependent on the presence of neutrophils during
the LPS exposure period [70]. Hence, it was concluded
that neutrophils may be a direct source of TGFβ1 follow-
ing their mobilisation into the submucosa, but may also
alter the subsequent expression of TGFβ1 in other airway
compartments, for instance the epithelium. In addition to
the epithelium, Lee and coworkers [89] have recently
demonstrated that neutrophil elastase increased the
expression of TGFβ1 in ASM cells, suggesting once again
that the mobilisation and activation of neutrophils into
the airways may increase TGFβ1 via indirect mechanisms.
Since TGFβ1 is also recognised as a potent trophic factor
for granulopoiesis [94] and was shown to recruit, activate
and prolong survival of neutrophils in other diseases [95],
TGFβ1 upregulation and neutrophilia observed in asthma
may mutually feedback each other, allowing the establish-
ment of a vicious cycle potentially involved in disease
exacerbation.
Eosinophils
In contrast to the aforementioned studies, Ohno and cow-
orkers [64] claimed that close to 100% of cells positive for
TGFβ1 mRNA in mild and severe asthma were eosi-
nophils, whereas these cells accounted for only 20.8% of
total TGFβ1 mRNA-positive cells in control subjects. Sim-
ilarly, Flood-Page and coworkers [67] have shown that
86% of cells positive for TGFβ1 mRNA in the bronchial
mucosa were eosinophils, and that 76% of the total eosi-
nophil population in this tissue compartment was immu-
nolabeled. These findings were substantiated by Minshall
and coworkers [65], who reported a coefficient of deter-
mination (R2) of 0.86 between TGFβ1 mRNA-positive
cells beneath the basement membrane and the degree of
eosinophilia in the same compartment. In this latter
study, 65% of the TGFβ1 mRNA positive cells were eosi-
nophils and 75% of eosinophils were positive for TGFβ1
mRNA. The remaining TGFβ1 mRNA positive cells were
identified as macrophages and fibroblasts [65]. Finally,
Vignola and coworkers [61] reported that eosinophilsRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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accounted for 80% of TGFβ1 mRNA positive cells in the
submucosa, the other 20% being fibroblasts.
As reported by Minshall and coworkers [65], many other
studies performed in humans or in animals bear witness
to the contention that eosinophils are a major cellular
source of TGFβ1 in asthmatic lungs by demonstrating a
linear relationship between the degree of eosinophilia
and the expression of TGFβ1 in different lung tissues. For
example, Nomura and coworkers [58] found a positive
correlation between eosinophil counts and the number of
cells staining positive for TGFβ1 in induced sputum sam-
ples of asthmatics. In a murine model of allergic asthma,
Tanaka and coworkers [96] reported a positive correlation
between the number of eosinophils and the level of
TGFβ1 in whole-lung lavage fluid. It was also proposed
that eosinophils from bronchial asthmatics are more
competent in TGFβ1 secretion compared to eosinophils
of control subjects, owing to their elevated TGFβ1 mRNA
[65] and protein [97] levels per cell.
In inflammatory conditions affecting the upper airways,
such as nasal polyps or allergic rhinitis, the cells express-
ing TGFβ1 gene in the mucosa specimens were also iden-
tified as being predominantly eosinophils [97]. The
proportion of eosinophils positive for TGFβ1 gene was
estimated at 50%. However, a great deal of TGFβ1 protein
in these specimens was not cell-associated, but rather
localized in the ECM associated with the vessels, the base-
ment membrane or within the submucosa [97]. This latter
result was consistent with several immunohistochemical
studies investigating the expression of TGFβ1 in lung spec-
imens [32,50,62].
IL-5 knockout mice also support the role for eosinophils
in TGFβ1 production. Compared to wild type animals, IL-
5-deficient mice chronically exposed to allergic challenge
showed a decreased expression of MBP positive cells,
which paralleled the reduction in the number of TGFβ
positive cells in the peribronchial region and a decrease in
TGFβ1 expression in whole lungs [98]. These changes in
TGFβ1 expression also correlated with fewer signs of air-
way remodeling. In accordance with this animal model,
treatment of mild atopic asthmatics for 2 months with
anti-IL-5 Ab (mepolizumab) was shown to be successful
in reducing tissue eosinophilia, lung TGFβ1 expression
and deposition of ECM components in the lamina reticu-
laris [67]. Therefore, the fact that both IL-5-deficient mice
[98] and asthmatics treated with anti-IL-5 Ab [67] demon-
strated fewer eosinophils, less TGFβ1 expression and
fewer signs of remodeling supports the notion that eosi-
nophils are an important source of TGFβ1 in the lungs of
asthmatics and that IL-5-dependent recruitment of eosi-
nophils is a prerequisite for TGFβ1-mediated airway
remodeling. However, it is worthy of mention that the sta-
tistically significant decrease in the median level of TGFβ1
in BALF reported by Flood-Page and coworkers [67] fol-
lowing anti-IL-5 Ab treatment was approximately 1 pg/ml,
which is unlikely to be physiologically relevant.
Macrophages
In the above study with IL-5-deficient mice, Cho and cow-
orkers [98] also demonstrated that 35% of TGFβ1 positive
cells in the peribronchial region were macrophages. In
humans, macrophages recovered in induced sputum sam-
ples also expressed TGFβ1 [58] and alveolar macrophages
from asthmatics released spontaneously higher amounts
of TGFβ1 relative to alveolar macrophages derived from
control subjects [99]. Similarly, Prieto and coworkers
[100] found higher level of TGFβ1 mRNA in alveolar mac-
rophages of mild atopic asthmatics compared to healthy
subjects. In Magnan and coworkers' study [63], TGFβ pos-
itive cells present in the submucosa of asthmatics were
mainly identified as lymphocytes, macrophages and, to a
lesser extent, eosinophils. In a transgenic model of asthma
induced by lung overexpression of IL-13, TGFβ1 mRNA
and protein were observed mainly in macrophages, but
also in type II pneumocytes, airway epithelial cells and
occasionally in eosinophils [16]. In a mouse model of
prolonged allergen challenge-induced airway remodeling,
the main source of TGFβ1 was identified as mononucle-
ated cells, likely macrophages [69]. Collectively, these
studies suggest that macrophages are a likely source of
TGFβ1 in asthma.
The higher levels of TGFβ1 mRNA in BALF-derived alveo-
lar macrophages (AM) observed by Prieto and coworkers
[100] in mild atopic asthmatics at baseline was not further
increased following repeated low-dose allergen inhala-
tion. Similarly, the increased release of TGFβ1 by alveolar
macrophages derived from asthmatics demonstrated by
Vignola and coworkers [99] was at baseline (i.e. without
prior allergen bronchoprovocation). These results suggest
that alveolar macrophages of asthmatics produce higher
amounts of TGFβ1 spontaneously. It equally raises the
possibility that the baseline overexpression of TGFβ1
observed in asthma by certain investigators [62,101] is
related to the increased production of this cytokine by
alveolar macrophages. The teleologic advantage of an
increased TGFβ1 production by these cells in asthma is
unknown. However, it is worth mentioning that alveolar
macrophages are predominant in the airways compared
to other cells mobilised into the airways following aller-
gen challenge or at baseline. Consequently, the mediators
they produce are susceptible to influence to a great extent
the pathologic outcomes. Of interest, alveolar macro-
phages were shown to be protective against asthma devel-
opment in a rat model of asthma [102]. Owing to the well
known immunosuppressive activity of TGFβ1, it is tempt-
ing to speculate that the increased expression of TGFβ1Respiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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observed in alveolar macrophages of asthmatics at base-
line may represent a regulatory mechanism to mitigate the
variable chronic ongoing inflammation during the stable
phase of the disease. In addition, and in contrast to other
airway cells, expression of TGFβ1 may not be altered in
macrophages following allergen challenge.
Mast cells
Unfortunately, the contribution of mast cells to the upreg-
ulation of TGFβ1 expression in asthma is not clear either.
Based on a study using mast cell-deficient mice (W/Wv
and Sl/Sld), Masuda and coworkers [103] have demon-
strated that the overall contribution of mast cells to the
upregulation of TGFβ1 expression in BALF of sensitized
and challenged mice was negligible. However, several
groups have demonstrated that mast cells were capable of
secreting TGFβ1 constitutively or upon stimulations in in
vitro conditions [104-106].
Epithelium
In contrast to Magnan and coworkers [63] who reported a
decreased expression of TGFβ in the epithelium of asth-
matics, some studies have pointed toward this tissue to
explain the increased expression of TGFβ1 in the airways
of asthmatic individuals [61,107]. Vignola and coworkers
[61] reported that TGFβ was faintly expressed in the air-
way epithelium of control subjects and was significantly
elevated in asthmatic subjects. Torrego and coworkers
[60] did not compared asthmatic and healthy control
individuals, but still agreed with this finding by showing
that the main cellular source of TGFβ1 in the bronchial
mucosa of mild atopic asthmatics was found in the epi-
thelium following either saline or allergen challenges. It
was also demonstrated that the spontaneous ex vivo
release of TGFβ1 was higher in airway epithelial cells
derived from asthmatic subjects compared to that derived
from non-asthmatic subjects [107]. In a model of sensi-
tized mice chronically challenged by inhalation of low
doses of antigen, Kumar and coworkers [56] have demon-
strated that TGFβ1 expression increased in airway epithe-
lial cells, but not in eosinophils or any other non-
epithelial cells. In addition, using laser capture microdis-
section and real-time PCR to quantify TGFβ1 mRNA levels
in lung sections of mice, Kelly and coworkers [54] demon-
strated that the TGFβ1 mRNA upregulation observed 2 wk
after chronic allergen exposure in sensitized animals was
confined to the airway epithelium.
Kumar and coworkers [56] have also shown that TGFβ1 in
airway epithelial cells of naïve animals is in its uncleaved,
biologically inactive form. Following chronic challenge of
sensitized mice with low doses of antigen, the cleaved and
biologically active form of TGFβ1 was found mainly in the
subepithelial zone in association with connective tissue
[56]. They suggested that the increased expression of
TGFβ1 in the subepithelial zone simply reflects deposi-
tion of epithelial cell-derived TGFβ1 onto the subjacent
ECM following its activation by antigen challenge. Hence,
the concept that the increased expression of TGFβ1 in the
submucosa originates from inflammatory cell infiltrates
makes no unanimous consensus among investigators in
the field. This result was consistent with observations
made by Kokturk and coworkers [62] on human tissues,
which confirmed the increased expression of TGFβ1 in the
airway submucosa of asthmatics despite the lack of a
simultaneous alteration in inflammatory cell infiltrate.
However, only asthmatics that were free from symptoms
for at least a month preceding the biopsy were included in
this latter study. It is thus possible that remnant (i.e. non-
utilised) inflammatory cell-derived TGFβ1 was stored in
the ECM after secretion and, as a result, would be respon-
sible for the increased TGFβ1 expression observed at a
time when cellular inflammation was resolved. Other-
wise, increased TGFβ1 expression may be produced by air-
way structural cells present in the submucosa such as
(myo)fibroblasts or ASM cells [62,69].
Kumar and coworkers [56] also suggested that the concen-
tration of antigen and the number of antigen exposures
are key elements determining which cells will preferen-
tially produce TGFβ1 in allergic asthma. They concluded
that eosinophils are the main TGFβ1-producing cells in
acute models of allergic asthma challenged with high
doses of antigen, but the epithelium is the main source of
this cytokine in sensitized animals chronically challenged
with low doses of antigen.
This increased TGFβ1 production by the airway epithe-
lium in asthma is consistent with numerous reports sug-
gesting that epithelial cell-derived TGFβ1 could be
upregulated upon different phlogogenic challenges in
vitro  [80,107-110], albeit conflicting results have been
reported [111]. Ex vivo cultures of bronchiolar epithelial
cells derived from smokers and from patients with COPD
also secrete higher amounts of TGFβ compared to those of
control patients [112]. In addition, TGFβ1 upregulation
in airway epithelial cells occurs by mechanical stress that
mimics bronchocontriction [113], as well as in several in
vivo conditions in addition to the aforementioned animal
models of asthma [54,56,98], including IL-13 transgenic
mice [16], and advanced pulmonary fibrosis [114] and
COPD [112] in humans.
The decreased expression of TGFβ in the airway epithe-
lium of asthmatics reported in some studies [63] may
reflect an active secretion of TGFβ. In this case, intracellu-
lar stores found in non-asthmatic epithelium would give
higher staining intensity for TGFβ by immunohistochem-
istry, but the latter would be reduced in asthmatics as
soon as the intracellular stores are emptied during theRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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course of the disease. Physiologically, this active TGFβ
secretion may be interpreted as an attempt by the epithe-
lium to buffer excessive ongoing inflammation. Alterna-
tively, a decreased immunoreactivity may represent a real
decrease in de novo synthesis of TGFβ1 by the asthmatic
epithelium. In this case, it may represent a well-regulated
process that favours inception or perennialization of air-
way inflammation.
Airway smooth muscle
The expression of TGFβ1 in ASM as been recognized for a
while [50,62,77,78,85-90], but studies that have com-
pared the expression between asthmatic and non-asth-
matic individuals are limited. Berger and coworkers [88]
were the first to demonstrate an increased expression of
TGFβ1 in ASM layer of persitent asthmatics compared to
non-asthmatic controls. More recently, Xie and coworkers
used laser capture microdissection to isolate ASM tissue
from bronchial biopsies, and have demonstrated that
ASM from asthmatic patients expressed higher mRNA and
protein amount of TGFβ1 [90]. These findings are consist-
ent with in vitro results showing that different stresses that
may be encountered by ASM in asthma, such as wounding
[87], neutrophil elastase [89], tryptase [88] and angi-
otensin II [86], trigger an increased TGFβ1 expression by
ASM cells. It was also reported that the chemotactic activ-
ity of ASM supernatant toward mast cells is related mainly
to TGFβ1 [88]. Together with the reported possitive corre-
lation between the levels of TGFβ1 expression and the
number of mast cells in the ASM tissue of an asthmatic
population [88], this ASM cell-derived, TGFβ1-mediated
mast cell migration may thus be involved in mast cell
myositis [115], which is a characteristic phenotypic fea-
ture of asthma [116].
Describing the pleiotropic functions of TGFβ1 on ASM
cells is beyond the scope of the present review. However,
it is well-established that in addition to being secreted by
ASM cell per se, this cytokine can, in turn, bind ASM cells
and influence their behavior in a way that can be
extremely relevant to further our understanding of asthma
pathogenesis [90,117-121].
Cellular sources of TGFβ1 in other types of airway 
inflammation
In other types of airway inflammation mediated by aller-
gen-independent mechanisms, such as the one induced
by prolonged LPS exposure, TGFβ1 also increased in
whole-lung lavage, as well as in the epithelium and the
submucosal compartments of the lung [122,123]. Simi-
larly, a single intratracheal delivery of an adenoviral vector
containing the proinflammatory cytokine IL-1β was suffi-
cient to increase the expression of TGFβ1 [124]. Together,
these findings suggest that TGFβ1 is induced downstream
of many causes of inflammation, probably acting as a
counterregulatory cytokine to resolve inflammation and
to initiate repair processes. If this conjecture is true, and
because asthma is an inflammatory condition of the air-
ways, it is expected that TGFβ1 would be upregulated in
asthmatic airways at a later time-point following chal-
lenge. In addition, since it is a cytokine ubiquitously
expressed, its cellular source in a particular disease may
originate from the cells triggered by the inflammatory sig-
nals or by the inflammatory cells mobilised to the site of
inflammation per se. Consequently, in the case of severe
asthma where neutrophils predominate, neutrophils
would be the main source of TGFβ1; and in the case of
mild to moderate asthma where eosinophils predomi-
nate, eosinophils would be the principal cells secreting
this cytokine. This hypothesis would reconcile many of
the conflicting results published so far and simply suggest
that TGFβ1 is upregulated as a general mechanism to cir-
cumvent inflammation and its secretion is ensured by any
cells present at the site of inflammation. Therefore, incon-
sistencies surrounding the cellular source of TGFβ1
expression in asthma may be related to either the hetero-
geneity of the asthma groups studied or to the particular
states of the disease (exacerbation vs remission period)
when the biopsies were taken.
Some weaknesses in the studies involved in the controver-
sial issue concerning the cellular source of TGFβ1 in
asthma are also worthy of mention: Firstly, the Ab used in
Magnan and coworkers [63], Vignola and coworkers [61],
and Chu and coworkers [66] did not discriminate
between the 3 isoforms of TGFβ and thus, the staining dis-
tribution and intensity is additionally confounded by
TGFβ2 and TGFβ3 expression. Secondly, the discrepancy
may also be related to the control group of Magnan and
coworkers [63], half of which were smokers and all
showed existing or suspected lung disease. Finally,
absence of medication withdrawal in the asthmatic group
before tissue collections in this same study could also
have led to erroneous results.
Active TGFβ signaling in asthma
Active TGFβ signaling, measured by nuclear immunos-
taining of phosphorylated Smad2 (pSmad2), has been
observed in airways of animal [125-127] and human
[128,129] asthmatics before and after allergic challenge.
Recent observations made by Torrego and coworkers [60]
further corroborates these results by showing an increased
nuclear staining of Smad4, together with an increased
expression of nuclear Smad2/3, in the bronchial mucosa
of mild atopic asthmatics 24 h post-allergen challenge.
Whether these observations are the result of an increased
expression of one or many of the TGFβ isoforms, their
desequestration from ECM or simply their activation
could be debated, but active signaling surely testifies thatRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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one or several of these processes are operational in
asthma.
However, it is noteworthy to mention that this increased
pSmad2 observed in asthma does not exclude the possible
involvement of other TGFβ family members in the activa-
tion of AR-Smads (Smad2/3). Activin A, in particular, has
recently gained interest in asthma pathophysiology. Both
mRNA levels in total lung [72] and BALF concentrations
[130] of Activin β A were upregulated following OVA sen-
sitization and challenge in mice. In humans, serum levels
of Activin A were shown to be elevated in moderate asth-
matics (1.16 ng/ml) compared to healthy individuals
(0.14 ng/ml) [72]. These studies suggest that increased
expression of pSmad2 following SAC may not be entirely
related to TGFβ1, but may also be due to other cytokines
of the TGFβ superfamily that signal via the AR-Smads,
such as Activin A. However, the serum levels of TGFβ1 is
more than 20-fold higher than those of Activin A [72]. In
addition, the latter is 10-fold less potent than TGFβ1 in
activating the Smad2/3 complex, as measured by transfec-
tion of human lung fibroblasts (IMR-90) with a Smad2/3-
responsive reporter gene [72]. It is thus believed that
TGFβ1 might outweigh the effect of Activin A, and conse-
quently, may represent the main contributor to Smad
nuclear translocation following allergen challenge.
TGFβ2 is also of particular interest in asthma. Two studies
that failed to identify an increased expression of TGFβ1 in
asthmatic airways have looked at TGFβ2 expression, and
both revealed significant increases [52,53,60]. In one of
these studies, Chu and coworkers [52] demonstrated a
higher level of TGFβ2 in the airway epithelium of asth-
matics compared to normal subjects. They further demon-
strated that TGFβ2, but not TGFβ1, is increased in primary
cultures of bronchial epithelial cells following IL-13 stim-
ulation. This result was supported by two previous arti-
cles, in which both IL-13 and IL-4 increased TGFβ2
production in bronchial epithelial cells [109,131]. In the
second study, Balzar and coworkers [53] quantified the
number of cells staining positive for TGFβ in the submu-
cosa. They demonstrated that among the 3 TGFβ iso-
forms, only TGFβ2 was increased in asthmatics. This
increased expression was also restricted to the group of
patients demonstrating the more severe form of the dis-
ease with persistent eosinophilia, which is surprisingly
similar to the finding published earlier by the same group
using a pan-TGFβ Ab [132]. Moreover, they showed that
tissue eosinophils from the severe group of patients
expressed higher amounts of TGFβ2 compared to tissue
eosinophils of control subjects or from patients suffering
from a milder form of the disease. Hence, in addition to
the increased production of TGFβ2 by the airway epithe-
lium in response to TH2 cytokines [52,109,131], eosi-
nophils in the submucosa could contribute to the overall
increase of TGFβ2 in the airways of severe asthmatics [53].
Elevated expression of TGFβ2 following bronchoprovoca-
tion was also demonstrated in two recent papers [55,60].
In these studies, TGFβ2 expression was increased in BALF
[55] and in the bronchial mucosa [60] 24 h after allergen
challenge. However, Batra and coworkers [55] also noted
a higher expression of TGFβ2 in non-asthmatics at base-
line as well as 1 and 2 weeks after SAC compared to asth-
matic subjects. In fact, only at 24 h post-SAC did TGFβ2
levels in BALF of asthmatics reach the concentration
found in non-asthmatics. Collectively, these results sug-
gest that TGFβ2 is increased in the airway epithelium of
asthmatics [52], as well as in eosinophils of a subgroup of
severe asthmatics [53], and even if its baseline expression
in the fluid harvested by bronchoalveolar lavage is lower
compared to non-asthmatics, it is transiently increased
after allergen challenge [55]. Since the TGFβ2 isoform acts
on the same receptors and signal via the same AR-Smads
as TGFβ1, these results indicate that TGFβ2 is also a likely
candidate to explain activation of Smad signaling in
asthma.
However, antibody to TGFβ1 was shown to prevent phos-
phorylation of Smad2 in a murine model of prolonged
allergen challenge-induced asthma [126]. This finding
suggested that TGFβ1 is responsible for the increased
expression of pSmad2 in the airways of asthmatics and
excluded the possible involvement of TGFβ2 or Activin A.
Interestingly, this anti-TGFβ1 Ab was administered fol-
lowing the establishment of eosinophilic inflammation,
and in addition to abrogating pSmad2 signaling in situ, it
reduced total and proliferating ASM cell numbers, mucus
production and peribronchiolar ECM deposition. These
results suggest that anti-TGFβ1 therapy can be envisaged
as a therapeutic approach (i.e. following the establish-
ment and the diagnosis of the disease), not only to reverse
fibrosis, but also to alleviate other features of airway dis-
ease in asthma.
In addition to active TGFβ signaling demonstrated by oth-
ers [125-129], Leung and coworkers [133] showed an
increased expression of Smad2/3 in ASM tissue of Brown
Norway rats sensitized and exposed to allergen. This result
indicates that the asthmatic state may prime ASM tissue to
respond in an excessive manner to TGFβ. This altered
expression of Smad2/3 was abrogated with oral adminis-
tration of SD-208, a pharmacological inhibitor targeting
ALK5, which suggests that TGFβ is involved in the upreg-
ulation of its own signaling intermediates that ensure its
signal transduction. Interestingly, both preventive and
curative treatments with SD-208 successfully abrogated
ASM cell hyperplasia. These treatments equally reduced
airway inflammation and goblet cell hyperplasia, suggest-Respiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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ing a potent pro-inflammatory action of TGFβ in asthma
in addition to its well-recognized function in airway
remodeling. These finding also highlight, once again, the
beneficial effect of a strategy preventing TGFβ signaling in
reversing established features of airway disease.
The anti-inflammatory effects observed with SD-208 are
counterintuitive to the well-known immunomodulatory
function of TGFβ1 [133]. In fact, several pieces of evidence
have shown that TGFβ1 counteracts excessive airway
inflammation. Examples include the following: 1-TGFβ1
heterozygous mice, which express 30% of the TGFβ1 pro-
tein level observed in the wild type animal, develop a
more severe form of the disease when exposed to an OVA
sensitization/challenge protocol [134]; 2- T lymphocytes
engineered to produce TGFβ1 or conditioned to secrete
higher amounts of TGFβ by oral tolerance reverse and
ameliorate, respectively, allergen-induced airway inflam-
mation [135,136]; and 3- blocking TGFβ signaling in T
cells by overexpressing Smad7 enhances allergen-induced
airway inflammation [129]. However, the findings
obtained with SD-208 indicate that considering TGFβ1
only as an immunosuppressive cytokine can be mislead-
ing. In support of the inflammatory role of TGFβ1 in
asthma, others have shown that its release by structural
cells in the airways contributes to inflammatory cell
recruitment [88,115]. In fact, TGFβ1 is a powerful chemo-
tactic factor for monocytes/macrophages [137], eosi-
nophils [138], neutrophils [139] and mast cells [140]in
vitro. Migration of monocytes/macrophages toward a gra-
dient of TGFβ1 occurs at concentrations in the femtomo-
lar range [137]. Additionally, TGFβ1 has been shown to
rescue murine macrophages from apoptosis [141]. In vivo,
the number of mast cells in ASM bundles was positively
associated with the ASM tissue expression of TGFβ1 [88].
Given the important function of mast cells in the patho-
physiology of allergic asthma [116], increased secretion of
TGFβ1 by structural cells in the airways following allergic
challenge may foster, rather than attenuate, inflamma-
tion.
Speculative argument
With all data taken together, one might imagine the fol-
lowing scenario of TGFβ1 regulation in asthma and its
potential role in the pathogenesis of the disease. In the
first stage of the disease, structural cell-derived TGFβ1 may
be released, or simply activated, to induce tissue infiltra-
tion of antigen presenting cells (APC, i.e. monocytes and
dentritic cells) and mast cells. Both of these cell types are
required for an immunologic response to take place in the
airways. On one hand, APC capture and process the aller-
gen and then migrate to regional lymph nodes to build a
T- and B-lymphocyte immunologic response. On the
other hand, mast cells home to the airway walls and will
bind to B-cell-derived IgE to produce an allergen-specific
reaction upon subsequent allergen exposure. In this sce-
nario, it is thus inferred that TGFβ1 is implicated in the
inception of allergic asthma by fostering the sensitization
process. In later stages of the disease (i.e. in already sensi-
tized individuals), TGFβ1 synthesis by structural cells may
stay downregulated for a while to favor the establishment
of lymphocytic and neutrophilic/eosinophilic inflamma-
tion. These mobilised inflammatory cells are first pro-
grammed to synthesize or secrete pro-inflammatory
mediators and to sequentially express and secrete immu-
nosuppressive cytokines, such as TGFβ1, to prevent exces-
sive inflammation and damage. At later time points, when
the bulk of inflammation is resolved, alveolar macro-
phages would maintain their higher secretion of TGFβ1
and the airway epithelium would start to express TGFβ1
again [54]. Increased expression of TGFβ1 by both of
these cellular sources may aim to get rid of remnant
inflammation and to pursue the healing response. In this
scenario, when TGFβ1 action is well regulated, restitution
of airway wall integrity would take place and airway func-
tion would be recovered. Otherwise, when TGFβ1 actions
are uncontrolled, airway remodeling would likely occur.
TGFβ1 receptors in asthma
TGFβ receptors are also expressed ubiquitously on mam-
malian cells [142-145]. In the lung, Tβ RI and Tβ RII were
identified in macrophages, as well as in epithelial, VSM,
ASM and endothelial cells of both conducting airways and
alveoli [78]. In contrast to its ligands, only few studies
have documented the regulation of these receptors in
asthmatic airways. Balzar and coworkers [53] have dem-
onstrated that Tβ R1 is downregulated in mild and severe
asthma. Similarly, Barbato and coworkers [146] have
reported a decrease in the number of cells positive for Tβ
RII in the subepithelium of children with asthma. Accord-
ing to the authors, these results may be indicative of active
TGFβ signaling, which is associated with TGFβ receptor
internalization. In contrast, wounding [119] as well as
granulocyte-macrophage colony-stimulating factor (GM-
CSF) treatment [147] have been shown to increase TGFβ
receptor expression in monocultures of ASM cells. Since
ASM cells are subjected to different kinds of damaging
stress and that GM-CSF is upregulated in the lungs of asth-
matic patients [61,148,149], these in vitro observations
will require further attention as they may actually subtan-
tiate the biological effect of TGFβ1 on ASM cells in vivo.
Conclusions and perspectives
Despite being extensively studied, the expression of
TGFβ1 in the airways of asthmatics still elicits more ques-
tions than answers. The current weight of evidence sug-
gests that TGFβ1 is upregulated in asthma. However,
whether its expression is altered at baseline or it is upreg-
ulated in a transient fashion following bronchoprovoca-
tion is not clear and may depend on the particular cellRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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and/or tissue studied. For instance, baseline expression of
TGFβ1 seems to be increased in alveolar macrophages
[99,100], but its expression in the airway lumen appears
to be inducible. In support to the latter contention, two
groups of investigators that have collected BALF following
SAC in human asthmatics have demonstrated that the
TGFβ1 level is transiently increased [49,55,150]. On the
other hand, the kinetics of TGFβ1 expression in the airway
epithelium of asthmatics seem to be more complex since
both upregulation [61,107] and downregulation [63]
have been reported. Studies looking at the kinetics of
TGFβ1 expression in this particular tissue following aller-
gen challenge should shed light on these conflicting
results.
As pointed out in this review, all the studies that were una-
ble to detect an altered protein expression of TGFβ1 in
asthma were investigating its expression levels by immu-
nohistochemistry. However, it is also important to men-
tion that certain investigators were capable to
demonstrate an increased expression of TGFβ1 in asth-
matic airways at baseline (i.e. without prior allergen chal-
lenge or apparent asthma exacerbation) by using
immunohistochemistry. For example, Minshall [65], Cha-
kir [68], Kokturk [62], Berger [88] and Xie [90] with their
respective coworkers have all previously shown an
increased intensity of staining or an increased number of
positive cells for TGFβ1 in the subepithelial region of asth-
matic airways. In most cases, it seems to be associated
with the severity of the disease [65,68,88] and the immu-
nohistochemical signal seems to originate from inflam-
matory cells infiltrating the submucosa [65,68] or ASM
[88,90]. Owing to the static picture obtained by staining
lung sections by immunohistochemical techniques and
because endobronchial biopsies in humans are performed
when the patients are free of symptoms, the lack of
increased expression of TGFβ1 reported by these groups of
investigators can reflect the failure to capture the transient
TGFβ1 upregulation. This may be the reason why more
immunohistochemical studies seem to be involved in the
controversial issue highlighted in this review. Alterna-
tively, reported inconsistencies may be the result of tech-
nical artefacts related to immunohistochemistry or to
inherent heterogeneity of asthma pathogenesis among
different populations.
Limitations with BALF procedure were also highlighted in
this review and it may thus be too soon to reject the pos-
sibility that TGFβ1 in not overexpressed in asthma. Stud-
ies designed to harvest tissues at multiple-time points
following allergic challenge would be very useful to
understand the kinetics of this cytokine regulation. Con-
sidering the invasive nature of trans- or endo-bronchial
biopsies or BALF, repeated measurements seem quite
unrealistic in human subjects. Less invasive techniques of
investigation, such as induced sputum [58,151] or
exhaled breath condensate [101], represent interesting
alternatives for these multiple time point studies and have
previously been used successfully to assess TGFβ1 expres-
sion in human subjects. The question that remains is to
what extent these techniques accurately reflect TGFβ1
expression in deeper airways. As such, the validity of these
techniques needs to be tested. Otherwise, identification of
other surrogates of lung TGFβ1 expression that could be
readily measured by these less invasive techniques would
be required. A last possibility to understand the kinetics of
TGFβ1 expression and activation would be to consider the
use of animal models.
In the meantime, increased expression of TGFβ1 has been
shown to occur exclusively in restricted localization in the
airways or only in particular subgroups of patients, such
as in severe asthmatics demonstrating prominent eosi-
nophilic inflammation [132]. Hence, in addition to tem-
poral concerns, spatial concerns need to be considered.
The fact that TGFβ1 may be differently involved in the
pathogenesis (or in the remission) of asthma in pheno-
typically distinct groups of asthmatics must also be appre-
ciated. In addition, a debate still persists concerning the
inflammatory cell that is mainly involved in the genera-
tion of TGFβ1 in asthma, as eosinophils, macrophages,
neutrophils, epithelial cells and ASM cells have all been
pointed out. Whether these conflicting results mirror the
heterogeneity of the disease in term of triggering agents,
individual genetic variability, history and severity of the
disease, or whether they are simply related to the time
points or the tissue chosen to measure TGFβ1 expression
are still unresolved questions and will required further
explorations.
Since TGFβ1 is released in an inactive form, its kinetics of
activation will also be relevant to elucidate its biological
or pathobiological functions in asthma. As highlighted in
this review, several points of regulation can influence the
final magnitude of the TGFβ1 response. All of these points
of regulation are as important as the expression of TGFβ1
per se if one attempts to appreciate the overall contribu-
tion of this cytokine in airway pathogenesis that character-
izes asthma. Unfortunately, studies investigating these
points of control are limited. On the other hand, several
studies indicate that TGFβ1 activity is increased in the air-
ways of asthmatics, as measured by intermediary end
points of TGFβ1 signaling (pSmads), which indicate that
TGFβ1 has been activated and has bound to its cognate
cell-surface receptor. These results suggest that if TGFβ1 is
not upregulated in asthma, other points of control must
be altered and this is ultimately translated into an
increased TGFβ1 activity. However, these results do not
exclude the involvement of other TGFβ superfamily mem-
bers that signal via the same Smads. But in this regard, oneRespiratory Research 2007, 8:66 http://respiratory-research.com/content/8/1/66
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study suggested that among these family members that
demonstrated an upregulated expression in asthma,
TGFβ1 is likely the main contributor to the increased
Smad signaling [126].
Dissecting the kinetics of TGFβ1 regulation following
bronchoprovocation will undoubtedly increase our
understanding of the inflammatory and fibrotic processes
that take place in asthma. Due to its large spectrum of bio-
logic effects, it is also unfortunately too soon to determine
whether TGFβ1 is the good guy or the nasty guy in asthma.
However, results obtained recently with anti-TGFβ1 Ab
[126] or with an ALK-5 inhibitor (SD-208) [133] in ani-
mal models of the disease are promising and suggest that
targeting TGFβ1 may be beneficial in the treatment of
human asthma.
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